TROP2和VEGFR2在三阴性乳腺癌中的表达及与临床病理因素的相关性研究

目的：观察人滋养层细胞表面抗原2（TROP2）和血管内皮生长因子受体2（VEGFR2）在三阴性乳腺癌中的表达及与临床病理因素和预后的相关性。方法：应用免疫组化（两步法）检测151例三阴性乳腺癌、137例非三阴性乳腺癌、48例乳腺良性肿瘤以及48例正常乳腺组织中TROP2和 VEGFR2的蛋白表达情况，结合临床病理资料综合分析其临床意义和预后价值。结果：TROP2和VEGFR2分别在乳腺癌细胞的细胞膜和细胞质表达。TROP2和VEGFR2蛋白在三阴性乳腺癌中高表达，阳性率高于非三阴性乳腺癌、乳腺良性肿瘤和正常乳腺组织，并且TROP2和VEGFR2共同在三阴性乳腺癌高表达，高于非三阴性乳腺癌，差异有统计学意义。三阴性乳腺癌组织中TROP2阳性表达、VEGFR2阳性表达，以及TROP2和VEGFR 2在三阴性乳腺癌中的共同高表达与患者的组织学分级、临床分期、远处转移有相关性。TROP2和VEGFR2蛋白共同高表达是三阴性乳腺癌的独立预后指标。结论：TROP2和VEGFR2可以作为三阴性乳腺癌新的分子靶点，有望用于三阴性乳腺癌的预后评价和免疫靶向治疗。

Expressions of TROP2 and VEGFR2 and their relationship with clinico-pathological factors in triple negative breast cancer

Objective:To observe the expression of human trophoblast cell surface antigen 2(TROP2)and vascular endothelial growth factor receptor 2(VEGFR2)in triple negative breast cancer and its correlation with clinical pathological factors and prognosis. Methods:The expression of TROP2 and VEGFR2 in 151 cases of triple negative breast cancer, 137 cases of non- triple negative breast cancer, 48 cases of benign breast tumor and 48 cases normal breast tissues were detected by immunohistochemical method(two-step method). Results:TROP2 and VEGFR2 expresse in the cell membrane and cytoplasm of breast cancer cells, respectively. The positive rate of TROP2 and VEGFR2 protein was higher than that of non- triple negative breast cancer,benign breast tumor and normal breast tissues.The co-expression of TROP2 and VEGFR2 in triple negative breast cancer was higher than that in non- triple negative breast cancer, and the difference was statistically significant. The positive expression of TROP2 and VEGFR2 was positive in triple negative breast cancer tissues and the co-expression of TROP2 and VEGFR2 in triple negative breast cancer was associated with histological grade,clinical stage and metastasis. The expression of TROP2 and VEGFR2 proteins is independent prognostic index of triple negative breast cancer. Conclusion: TROP2 and VEGFR2 can be used as a new molecular target for triple negative breast cancer, and which is expected to be used for the prognosis evaluation and immune-targeting treatment of triple negative breast cancer.